The first mention of "biogenic stimulants" in scientific literatures dates from the thirties. In the seventies, the first amino acid biostimulants were produced and sold for the agricultural market.

In 2007, Damaco Group initiates R&D into poultry protein hydrolysates in collaboration with Italian and Russian universities and with support from the European Commission.

In 2013, we started with the construction of a new facility in Dendermonde, dedicated to the production of protein hydrolysates. Production  of the first hydrolysates starts in 2015.

In 2016, we initiated the first experiments with an early version of the Aphasol amino acid biostimulant on plants.

2018 marked the start of our collaboration with the University of Ghent, with the first Aphasol lab tests to identify the active ingredients and analyse the specific biostimulating effects.

In 2019, we conducted the first field trials on row crops, with convincing results.

Stam Agro was established in 2020 as Damaco's dedicated "nutrient science" R&D division, responsible for the further development of Aphasol. The number of Aphasol field and farm trials increased exponentially.

The Aphasol brand was launched at the end of 2021, after another successful trial season.

2021 also marked the start of a € 1.3 million VLAIO research project in collaboration with Ghent University to further develop and extend the Aphasol product line.

Impressive 2022 sales figures are fully reinvested in further research and continued growth.

A total of 20 trials by expert research centers is complemented by more than 50 farm trials. All spread over a dozen of crops on 2 continents.

2023 marks the start of our internationalisation. With registrations in several European countries and doubling of the number of crop trials.